Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity
about
Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.LAG3 (CD223) as a cancer immunotherapy target.HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.Immune and molecular correlates in melanoma treated with immune checkpoint blockade.The controversial role of TNF in melanoma.Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes.T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.Detection of ABCB5 tumour antigen-specific CD8+ T cells in melanoma patients and implications for immunotherapy.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.CD4+ T cell-mediated cytotoxicity eliminates primary tumor cells in metastatic melanoma through high MHC class II expression and can be enhanced by inhibitory receptor blockade.Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.Immunotherapy in managing metastatic melanoma: which treatment when?Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
P2860
Q30235983-BBBADB78-75F6-4460-8994-1D90AA4465A0Q33688931-6E01DEF0-F052-41C5-9FB3-79CD33D1CDEFQ39160974-E7C2B6EE-3F4E-4C64-9A5C-48AFE2F40BF4Q39244731-A4DC69B0-DF6F-4525-8D0C-429FF0949BB9Q39329603-37A00D71-5FD1-4775-8D2E-BB9B97AF0783Q40437125-19EA5EAE-9D8D-4785-8697-948E13D54424Q40603434-1D70C05B-3307-4C03-84F5-FA8E1E7FBA4FQ42333881-90AED2A3-50DE-4795-AB63-A56D1378CC67Q47865137-80CE73D0-FF61-47E2-BE76-62163B55E25EQ48185876-368A33DE-4BF4-40F9-905F-DDB4C39A107CQ49011434-A1EFD5D9-CBAB-4627-8D12-E5C8F42C0F73Q49432766-CB20990F-BE9A-48FE-A1C9-BCBA7EC29019Q49605941-C0FBA55F-C956-471D-AC4C-F26086A4F5EEQ50166276-5F6B4EBE-DFC0-41D5-93FE-933B3FD602D6Q58781616-6231AC97-1C99-4AB5-A831-2015A3F3C366
P2860
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@ast
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@en
type
label
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@ast
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@en
prefLabel
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@ast
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@en
P2093
P50
P1433
P1476
Aberrant Expression of MHC Cla ...... + T-cell Antitumor Reactivity
@en
P2093
Ferdinando Nicoletti
Julie W. Kjeldsen
Paolo Fagone
Rikke Andersen
Shamaila Munir
P304
P356
10.1158/0008-5472.CAN-14-2956
P407
P577
2015-07-16T00:00:00Z